174 related articles for article (PubMed ID: 22834877)
21. Xanthines and skeletal muscle: lack of relationship between phosphodiesterase inhibition and increased twitch tension in rat diaphragms.
Kramer GL; Wells JN
Mol Pharmacol; 1980 Jan; 17(1):73-8. PubMed ID: 6247639
[No Abstract] [Full Text] [Related]
22. Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition.
Jones PG; Hewitt MC; Campbell JE; Quinton MS; Engel S; Lew R; Campbell U; Burdi DF
Pharmacol Biochem Behav; 2015 Aug; 135():46-52. PubMed ID: 25989044
[TBL] [Abstract][Full Text] [Related]
23. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
Gibson LC; Hastings SF; McPhee I; Clayton RA; Darroch CE; Mackenzie A; Mackenzie FL; Nagasawa M; Stevens PA; Mackenzie SJ
Eur J Pharmacol; 2006 May; 538(1-3):39-42. PubMed ID: 16674936
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
25. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
26. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.
Seftel AD
J Urol; 2005 Sep; 174(3):1043. PubMed ID: 16094045
[No Abstract] [Full Text] [Related]
27. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
28. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.
Yang H; Murigi FN; Wang Z; Li J; Jin H; Tu Z
Bioorg Med Chem Lett; 2015 Feb; 25(4):919-24. PubMed ID: 25592707
[TBL] [Abstract][Full Text] [Related]
30. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
31. [Active role of phosphodiesterases in regulation of cyclic AMP metabolism in the thyroid gland (proceedings)].
Erneux C; Boeynaems JM; Van Sande J; Dumont JE
Arch Int Physiol Biochim; 1976 Dec; 84(5):1070-2. PubMed ID: 65996
[No Abstract] [Full Text] [Related]
32. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions.
Davis CW
Biochim Biophys Acta; 1984 Mar; 797(3):354-62. PubMed ID: 6320906
[TBL] [Abstract][Full Text] [Related]
33. A novel compound JPM8: in vivo penile activity promotion in rats, effect on the relaxation and cGMP/cAMP accumulation in isolated rabbit corpora cavernosa.
El-Thaher TS; Khatib S; Saleem M; Shnoudeh A; Badwan AA
Int J Impot Res; 2002 Dec; 14(6):453-61. PubMed ID: 12494277
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of neoplastic cell growth by quiescent cells is mediated by serum concentration and cAMP phosphodiesterase inhibitors.
Bertram JS; Bertram BB; Janik P
J Cell Biochem; 1982; 18(4):515-38. PubMed ID: 6282911
[No Abstract] [Full Text] [Related]
35. Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).
Zagórska A
Expert Opin Ther Pat; 2020 Feb; 30(2):147-157. PubMed ID: 31874060
[No Abstract] [Full Text] [Related]
36. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
37. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
38. Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells.
Kim NN; Huang Y; Moreland RB; Kwak SS; Goldstein I; Traish A
Mol Cell Biol Res Commun; 2000 Jul; 4(1):10-4. PubMed ID: 11152621
[TBL] [Abstract][Full Text] [Related]
39. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2.
Sano H; Nagai Y; Miyakawa T; Shigemoto R; Yokoi M
J Neurochem; 2008 Apr; 105(2):546-56. PubMed ID: 18088367
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
Kehler J
Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
